Loading organizations...
Rhapsody Venture Partners operates as a venture capital firm, dedicating its investments exclusively to hard science startups. The firm primarily focuses on early-stage seed rounds, acting as a lead investor for companies developing solutions to industrial challenges. Their approach centers on fostering the transition of scientific breakthroughs into tangible, market-ready applications.
Established in 2016, Rhapsody Venture Partners is headquartered in Cambridge, Massachusetts. The genesis of the firm was rooted in the insight that deep technological innovation requires dedicated support and co-creation with scientific founders. This led to the establishment of a partnership model designed to help these ventures navigate the complexities of bringing advanced technologies from the lab to industry.
The firm's clientele consists of scientific founders aiming to deploy their sophisticated technologies into the world. Rhapsody Venture Partners partners with these entrepreneurs, guiding their progress. Their overarching vision is a belief that robust hard tech innovation serves as a fundamental driver for establishing a sustainable and prosperous world.
Key people at Rhapsody Venture Partners.
Rhapsody Venture Partners is a venture capital firm headquartered in Cambridge, Massachusetts, specializing in early-stage investments in hard tech and industrial science startups.[1][2][3][5] Their mission centers on co-creating and nurturing innovations in hard sciences, including materials science, engineering, chemistry, food technology, energy, life sciences, agriculture, and consumer products, by leveraging a network of scientists and experts to accelerate transformative solutions for sustainability and industrial challenges.[1][3][4] The firm's investment philosophy emphasizes data-driven partnerships, operational support, and active involvement in portfolio companies, drawing from managers' experience in over 50 tech and healthcare deals across North America and Europe, with notable biotech exits.[1] Rhapsody significantly impacts the startup ecosystem by leading seed and pre-seed rounds in university spinouts (e.g., Harvard, MIT, Caltech, Wyss Institute), bridging academic breakthroughs to commercial scale and fostering hard tech entrepreneurship amid rising demand for sustainable technologies.[4][5]
Rhapsody Venture Partners traces its roots to 2012, when it was founded in Cambridge, Massachusetts, initially focusing on investing in and operating industrial science startups.[2] Some sources note activity ramping up around 2016, aligning with the launch of dedicated funds.[5] Key figures include Managing Partner Carsten Boers, General Partner Bernard Lupien, and Principals Corrie Kavanaugh and Isabel Klein, who bring expertise in technology, healthcare, and strategic investments.[1][5] The firm's evolution has centered on hard tech, shifting from broad industrial science to specialized early-stage hard innovations like advanced materials and biomanufacturing, evidenced by funds closed in 2018, 2020, and a 2022 vintage still in market.[5] This progression reflects a deepening commitment to hands-on co-creation, exemplified by early bets like co-leading Chinova's 2018 pre-seed with DSM.[4]
Rhapsody rides the hard tech resurgence, capitalizing on trends like sustainable materials, advanced energy storage, and bio-based manufacturing amid climate imperatives and supply chain reshoring.[1][4] Timing is ideal post-2020, as industrial science startups address post-pandemic needs for resilient, green tech—e.g., mushroom-based preservatives (Chinova) reducing artificial ingredients, or solid-state batteries (Adden) enabling faster EV adoption.[4] Market forces like U.S. policy support for domestic innovation (e.g., CHIPS Act influences) and VC shift toward deep tech favor their model, with university spinouts providing a pipeline of defensible IP.[2][4] They influence the ecosystem by de-risking hard tech commercialization, proving mass-market viability (e.g., NODAR's 3D perception for affordable autonomy), and inspiring follow-on capital from players like SOSV and AgFunder.[4]
Rhapsody is poised to expand its portfolio in high-growth hard tech niches like advanced batteries and bioengineered foods, potentially closing larger funds to fuel follow-ons amid maturing exits.[4][5] Trends such as AI-accelerated materials discovery and global sustainability mandates will amplify their edge, especially with U.S.-centric focus amid geopolitical shifts.[3] Their influence may evolve toward larger syndicates and operator-led scaling, solidifying Cambridge as a hard tech hub—echoing their core strength in turning lab breakthroughs into ecosystem-defining companies.[1][2]
Key people at Rhapsody Venture Partners.
Rhapsody Venture Partners has 19 tracked investments across 13 companies. The latest tracked deal is $25.6M Series B in pH7 in December 2025.
